FFT Wealth Management LLC Has $359,000 Stake in Eli Lilly and Company $LLY

FFT Wealth Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 82.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 334 shares of the company’s stock after selling 1,535 shares during the period. FFT Wealth Management LLC’s holdings in Eli Lilly and Company were worth $359,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Nia Impact Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $233,000. CYBER HORNET ETFs LLC lifted its position in shares of Eli Lilly and Company by 5.2% in the fourth quarter. CYBER HORNET ETFs LLC now owns 2,312 shares of the company’s stock valued at $2,485,000 after buying an additional 115 shares during the last quarter. Westover Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 9.9% in the fourth quarter. Westover Capital Advisors LLC now owns 2,071 shares of the company’s stock valued at $2,226,000 after buying an additional 187 shares during the last quarter. Clearstead Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.4% in the fourth quarter. Clearstead Advisors LLC now owns 49,407 shares of the company’s stock valued at $53,097,000 after buying an additional 679 shares during the last quarter. Finally, Churchill Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $782,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,066.59 on Monday. The stock has a market capitalization of $1.00 trillion, a PE ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business has a fifty day moving average price of $942.87 and a two-hundred day moving average price of $1,004.53. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. Morgan Stanley reissued an “overweight” rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a report on Friday, May 1st. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a report on Thursday. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. TD Cowen lifted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Scotiabank reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.